- Consolidative allogeneic hematopoietic stem cell transplant (allo-HSCT) following chimeric antigen receptor T (CAR-T) cell therapy delivered significant improvements in event-free survival (EFS) and relapse-free survival (RFS) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and high (≥5%) preinfusion bone marrow minimal residual disease by flow cytometry (BM-FCM-MRD) or poor prognostic markers.
Why this matters
- Patients who have achieved complete remission (CR) with CAR-T cell therapy remain at high risk of relapse.
- Study to investigate allo-HSCT following anti-CD19 CAR-T cell therapy in 58 patients with R/R B-ALL.
- Funding: National Natural Science Foundation of China; Major Technological Innovation Special Project of Hubei Province of China.
- 58 patients received CAR-T cell therapy, among whom 87.9% achieved CR.
- No significant difference in OS in patients with vs without transplant: P=.099.
- Improved EFS with transplant vs without: P=.021.
- Improved RFS with transplant vs without: P=.001.
- Significantly improved EFS and RFS in transplanted patients with:
- High (≥5%) BM-FCM-MRD: P=.032 and .0031, respectively.
- Preinfusion BM-FCM-MRD
- Nonrandomized study.